What Is DME?
For the nearly 21 million Americans living with diabetes2, vision loss
is a common complication. Diabetic macular edema is one of three forms of retinopathy,
the leading cause of legal blindness in Americans aged 55-74.3
Macular edema occurs when leaky blood vessels cause part of the eye (the retina)
to become thick or swollen. As the condition worsens, it may cause blurred and distorted
vision.
Prevalence
People living with diabetes are at greater risk for experiencing vision loss than
people without diabetes.4 Approximately 14 percent of people with diabetes
have diabetic macular edema, according to the International Diabetes Federation.5
According to the International Diabetes Federation, approximately 25 percent of
people with diabetic macular edema may develop moderate vision loss within three
years.6
One in four African-American women over 55 years of age has diabetes7,
and approximately 40 percent of people with diabetes develop problems with their
eyes.8
Diabetes is a leading health problem for Hispanics and the primary cause of vision
loss in America. Nearly half of all adult Hispanics in the United States living
with diabetes are coping with a form of vision loss known as diabetic retinopathy,
of which, diabetic macular edema (DME) makes up 10 percent of those cases.9
2 American Diabetes Association: www.diabetes.org/diabetes-statistics/prevalence.jsp
3 Klein R, Klein BEK. "Vision disorders in diabetes." Diabetes in
America. 2nd ed. NIH Publication No. 95-1468, 1995
4 American Diabetes Association: http://diabetes.org/type-1-diabetes/eye-complications.jsp
5 International Diabetes Federation: www.idf.org/home/index.cfm?node=1155
6 Ibid
7 http://diabetes.org/communityprograms-and-localevents/africanamericans.jsp
8 http://www.nei.nih.gov/nehep/plans/diabetesplan.asp
9 http://www.nei.nih.gov/news/statements/latinostudy.asp
Are you eligible?
If you have diabetes and are living with macular edema, you may qualify to participate
in one of two national research studies which will provide information about the
safety and effectiveness of an investigational drug in DME.
Please
take the online survey
to answer questions that may help determine eligibility for the two studies.